GlassScriptPhysician profile
Tracy C Moore
NPI 1417188558
$4,918.64
in general payments reported to CMS, 2019-2025
25 companies · $567 in 2025
The $567 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $692 · 2022: $963 · 2023: $979 · 2024: $1,717 · 2025: $567.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,143 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,143.18 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $120.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $513.16 | 2021-2023 | |
| Genzyme Corporation | $372.46 | 2021-2024 | |
| Evoke Pharma, INC. | $351.51 | 2022-2024 | Gimoti |
| Gilead Sciences, INC. | $332.19 | 2022-2024 | Epclusa |
| Idorsia Pharmaceuticals US INC | $315.06 | 2024 | Tryvio |
| Phathom Pharmaceuticals, INC. | $245.66 | 2024-2025 | Voquezna |
| Sanofi-Aventis U.S. LLC | $245.38 | 2024 | |
| Novo Nordisk INC | $245.13 | 2022-2025 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $244.85 | 2021-2024 | Airsupra |
| Ultragenyx Pharmaceutical INC. | $225.04 | 2022-2023 | Crysvita |
| Astellas Pharma US INC | $216.22 | 2024 | Cresemba, Veozah |
| Otsuka America Pharmaceutical, INC. | $210.11 | 2023-2024 | Rexulti, Nuedexta |
| Sumitomo Pharma America, INC. | $209.32 | 2024-2025 | Gemtesa, Myfembree |
| Mayne Pharma Commercial LLC | $154.82 | 2024-2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $153.67 | 2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $152.07 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $122.11 | 2023 | |
| Mylan Specialty L.P. | $120.68 | 2023 | Yupelri |
| Neurocrine Biosciences, INC. | $108.29 | 2022 | |
| Paratek Pharmaceuticals, INC. | $100.49 | 2022 | |
| Neurelis, INC. | $93.00 | 2025 | Valtoco |
| Novartis Pharmaceuticals Corporation | $64.64 | 2021 | |
| Janssen Pharmaceuticals, INC | $52.57 | 2025 | Spravato |
| Axsome Therapeutics, INC. | $39.68 | 2023 | Auvelity |
| Exeltis, USA INC. | $30.53 | 2025 | Twirla, Slynd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracy Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.